MetaCap

Annovis Bio (ANVS) vs Rallybio (RLYB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rallybio (RLYB) has outperformed Annovis Bio (ANVS) over the past year, gaining 208.4% versus a loss of 81.2%. Over five years, RLYB leads with a -85.3% price change compared with -97.2% for ANVS. Annovis Bio is the larger company by market cap ($44.1 million vs $43.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANVS-81.23%RLYB+208.41%
+260%+80%-99%
Nov 21, 20251 yearNov 20, 2026
ANVS-97.38%RLYB-85.73%
+13%-45%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANVS versus RLYB key metrics
MetricANVSRLYB
Share price$0.7113$15.47
Market cap$44.12M$43.32M
1-day change-4.96%-0.32%
YTD return-79.44%+181.89%
1-year return-81.23%+208.41%
5-year return-97.24%-85.29%
P/E ratio (TTM)—3.36
EPS (TTM)$-1.55$4.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$858.00K
Revenue growth (YoY)—+34.91%
Net income (latest FY)$-28.85M$-8.98M
Operating margin—-3853.61%
Net margin—-1046.39%
52-week high$5.50$35.15
52-week low$0.62$7.34
Distance from 52-week high-87.07%-55.99%
Analyst consensusnone—
Avg. price target upside+1376.17%—
Average volume1.82M10.14K
Shares outstanding62.02M2.80M
Employees77
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLYB has outperformed ANVS by 289.6 percentage points over the past year.

About Annovis Bio

ANVS stock →

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Rallybio

RLYB stock →

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ANVS vs RLYB FAQ

Which is bigger, Annovis Bio or Rallybio?

Annovis Bio (ANVS) is larger, with a market capitalization of $44.12M compared with $43.32M for Rallybio (RLYB).

Which stock has performed better over the past year, ANVS or RLYB?

RLYB returned +208.41% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.

Are Annovis Bio and Rallybio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons